Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases

Autor: Masaki Ishikawa, Shintaro Takaki, Yuki Kimura, Kazuaki Chayama, Tomokazu Kawaoka, Akira Hiramatsu, Masashi Hieda, Shoichi Takahashi, Hiroshi Aikata, Yoshiiku Kawakami, Koji Waki, Yoshio Katamura, Hideaki Kakizawa
Rok vydání: 2010
Předmět:
Zdroj: Journal of Gastroenterology and Hepatology. 25:1117-1122
ISSN: 0815-9319
DOI: 10.1111/j.1440-1746.2009.06110.x
Popis: Background and Aims: We investigated the efficacy of intra-arterial 5-fluorouracil (5-FU) and systemic interferon (IFN)-α (5-FU-IFN) in the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis in the first branch or trunk (Vp3/4) and extrahepatic metastases. Methods: We examined 17 HCC patients with Vp3/4 and extrahepatic metastases (meta group) and 31 HCC patients with Vp3/4 (non-meta group). Baseline intrahepatic tumor factors and the hepatic reserve were similar between groups. The extrahepatic metastases of the meta group were not considered prognostic factors. Following the administration of 5-FU/IFN to all patients, we compared the survival rates, response, time to progression (TTP), and safety between groups. Results: For intrahepatic HCC, complete response, partial response, stable disease, progressive disease, and drop out were observed in no (0%), one (6%), seven (41%), nine (53%), and no (0%) patients of the meta group, and in five (16%), seven (23%), 13 (42%), five (16%) and one (3%) patient of the non-meta group, respectively. The response rate was significantly lower in the meta group (6% vs 39%, P = 0.018). The median TTP of intrahepatic HCC and the median survival time were significantly shorter in the meta group than in the non-meta group (1.6 vs 6.3 months, P = 0.0001, and 3.9 months vs 10.5 months, P
Databáze: OpenAIRE